High-Dose Dual Therapy for H. Pylori Eradication (RETRO-HP Study)
Key facts
- Who runs it
- Liyueyue
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,600 people enrolled
- Started
- 1 Jun 2025
- Ended
- 20 Jul 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- Record updated
- 13 August 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- (1) patients aged 18-70 years, regardless of gender; (2) absent history of receiving H. pylori eradication therapy; (3) diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination
Who cannot take part
- (1) patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments; (2) patients who received treatment regimens that did not conform to the standardized HDDT protocol specified in this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
High-dose dual therapy (HDDT) has emerged as a potential first-line treatment for Helicobacter pylori infection, but its efficacy and safety across different regimens and populations remain unclear. This study aimed to compare real-world outcomes of various HDDT protocols and identify factors influencing treatment failure.
Methods:
A multicenter retrospective analysis was conducted using data from 15 medical centers (January 2022-January 2025). Patients received one of four HDDT regimens: vonoprazan-amoxicillin for 10 days (VA-10) or 14 days (VA-14), esomeprazole-amoxicillin (EA), or tegoprazan-amoxicillin (TA). Primary outcomes included eradication rates (modified intention-to-treat analysis) and adverse events.
The 4 groups in the trial
- VA-10 day group
Treatment: This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- VA-14 day group
Treatment: This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- TA group
Treatment: This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- EA group
Treatment: This study is a retrospective study, and all data have been collected in advance with no active intervention required.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter Pylori Eradication: A Multicenter Retrospective Study
- Record updated
- 13 August 2025